Active Stocks
Tue Mar 19 2024 15:58:41
  1. Tata Consultancy Services share price
  2. 3,977.55 -4.03%
  1. Tata Steel share price
  2. 148.65 -0.64%
  1. Bharti Airtel share price
  2. 1,227.85 0.23%
  1. Power Grid Corporation Of India share price
  2. 258.95 -2.28%
  1. ITC share price
  2. 409.50 -1.89%
Business News/ Companies / Dr Reddy’s gets USFDA nod for Ranitidine
BackBack

Dr Reddy’s gets USFDA nod for Ranitidine

Dr Reddy’s gets USFDA nod for Ranitidine

Premium

PTI

New Delhi: Pharma major, Dr Reddy’s Laboratory, said on 13 September it has got the approval of US Food and Drug Administration (USFDA)for the company’s Abbreviated New Drug Application (ANDA) for Ranitidine (Zantac) tablet in 150 mg strength, used in the treatment of Stomach and duodenal ulcers.

Dr Reddy’s Laboratory is the only generic manufacturer to receive FDA approval for this product and is also the first approval for the company’s US Over The Counter (OTC) drug business.

“We are excited about the Ranitidine approval as it would help in establishing Dr Reddy’s in US OTC business segment. The company has plans to expand its OTC product portfolio and additional introductions are planned in the coming months," North America Generics president Mark Hartman said in a statement.

Dr Reddy’s had, earlier in May, announced its plans to launch store brand OTC Division in the US and the company already had the USFDA nod for the tablet in 75 mg strength.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 13 Sep 2007, 02:32 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie